EDP Biotech Corporation Announces CE Mark Approval For Colomarker An In Vitro Diagnostic Aid In Early Detection Of Colon Cancer And Plans For Commercialization In Europe
KNOXVILLE, Tenn.--(BUSINESS WIRE)--EDP Biotech Corporation, (“EDP,” or the “Company”), a global in vitro diagnostic innovator of life-saving, easy-to-use cancer diagnostic tests using ELISA technology, has announced CE Mark approval for ColoMarker® , an aid in early detection of Colon Cancer. This is a critical step toward commercialization of this unique product which will initially be introduced in the thirty member states belonging to the European Economic Area (EEA).
The EDP ColoMarker® test is a quick and easy tool for clinicians as an aid in early detection of colon cancer when it is most treatable, and only requires a small sample of blood. EDP expects that ColoMarker’s® affordable cost (priced somewhere between IFOBT and FIT stool tests), effectiveness, and the convenience of a whole blood test will significantly improve compliance compared to colonoscopy-based cancer screenings and existing fecal testing options.
Help employers find you! Check out all the jobs and post your resume.
The EDP ColoMarker® test is a quick and easy tool for clinicians as an aid in early detection of colon cancer when it is most treatable, and only requires a small sample of blood. EDP expects that ColoMarker’s® affordable cost (priced somewhere between IFOBT and FIT stool tests), effectiveness, and the convenience of a whole blood test will significantly improve compliance compared to colonoscopy-based cancer screenings and existing fecal testing options.
Help employers find you! Check out all the jobs and post your resume.